TS
TARA icon

Thomas Steyer’s Protara Therapeutics TARA Stock Holding History

Thomas Steyer’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-425,000
Closed -$7.15M – 151
2020
Q3 		$7.15M Buy
+425,000
New +$9.86M 0.05% 103

Other funds holding TARA

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Thomas Steyer's TARA Position: Q4 2020 in Review

Thomas Steyer sold out of Protara Therapeutics (TARA) in Q4 2020, closing a stake of 425,000 shares — an estimated $7.15M sold.

Thomas Steyer first reported a position in TARA in Q3 2020 and held it in 1 quarter. The position peaked at $7.15M in Q3 2020. 49 funds tracked by Wall St. Rank hold TARA as of Q4 2020.

  • Thomas Steyer reported no remaining Protara Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Thomas Steyer sold 425,000 Protara Therapeutics shares in Q4 2020, an estimated $7.15M.
  • Thomas Steyer first reported a position in Protara Therapeutics in Q3 2020 and held it in 1 quarter.
  • Thomas Steyer's Protara Therapeutics position peaked at $7.15M in Q3 2020.
  • 49 funds tracked by Wall St. Rank held Protara Therapeutics as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.